Brammer Bio – UF Innovate

INOVIO Adds Thermo Fisher Scientific To Global Manufacturing Consortium

Sara Dagen — Wed, 09 Sep 2020 00:00:00 +0000

Inovio, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that Thermo Fisher Scientific, the world leader in serving science, has signed a letter of intent to manufacture INOVIO’s DNA COVID-19 vaccine candidate INO-4800.

Thermo Fisher Scientific will join existing partners Richter-Helm BioLogics and UF startup and UF Innovate | Sid Martin Biotech alum Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), in INOVIO’s global manufacturing consortium.

Thermo Fisher Scientific Inc., acquired UF Innovate | Sid Martin Biotech alum Brammer Bio in 2019, founded by UF researcher Dr. Richard Snyder.

Learn more about INOVIO Adds Thermo Fisher Scientific To Global Manufacturing Consortium.

$6 Million Expansion for Gene Therapy Facility Completed at Alachua’s Progress Park

Sara Dagen — Mon, 25 Nov 2019 00:00:00 +0000

Local and state officials gathered in Alachua to commemorate a $6 million expansion at Progress Park.

Representatives of Thermo Fisher Scientific Inc., a global science company involved with research and biotechnology product development, presented the company’s expanded gene therapy and viral vector services site. The day included tours of the 95,000-square-foot facility.

University of Florida’s Assistant Vice President of Technology Commercialization Jim O’Connell was present during the unveiling. O’Connell noted that the research started 16 years ago at the University of Florida when Richard Snyder founded Florida Biologix, which changed to Brammer Bio through a merger with Brammer Biopharmaceuticals in 2016. Brammer Bio then merged with Thermo Fisher Scientific in May 2019.

Learn more about $6 Million Expansion for Gene Therapy Facility Completed at Alachua’s Progress Park.

The $1.7 Billion Deal: Sale of Brammer Bio Moves Region Toward Bio Hub

Sara Dagen — Tue, 07 May 2019 00:00:00 +0000

The sale of Greater Gainesville company Brammer Bio for $1.7 billion in April is a big step toward the region becoming a hub for biotechnology, business, and educational leaders.

Thermo Fisher Scientific, which calls itself “the world leader in serving science” and employs 70,000 people, bought UF spinout company Brammer Bio – making it a major player in helping companies develop gene therapy.

Learn more about The $1.7 Billion Deal: Sale of Brammer Bio Moves Region Toward Bio Hub.

Thermo Fisher Scientific Completes Acquisition of Brammer Bio

Sara Dagen — Fri, 03 May 2019 00:00:00 +0000

Thermo Fisher Scientific Inc., the world leader in serving science, announced that it has completed its previously announced acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, for approximately $1.7 billion in cash. The completion of the transaction follows the receipt of all required regulatory approvals.

Brammer Bio has nearly 600 employees at primary locations in Massachusetts and Florida and will become part of Thermo Fisher’s Pharma Services business within its Laboratory Products and Services Segment.

Learn more about Thermo Fisher Scientific Completes Acquisition of Brammer Bio.

Thermo Fisher to Acquire Brammer Bio in $1.7 Billion Gene-Therapy Deal

Sara Dagen — Mon, 08 Apr 2019 00:00:00 +0000

Thermo Fisher Scientific Inc. said it is buying Alachua-based Brammer Bio for $1.7 billion in a move that would expand the lab-equipment company’s presence in the rapidly growing field of gene therapy.

Closely held Brammer Bio, owned by private-equity firm Ampersand Capital Partners, provides pharmaceutical companies developing gene therapies and gene-modified cell therapies with outsourced research and drugmaking services.

Gene therapies aim to replace defective genes with healthy ones, and researchers consider them to be a promising treatment option for intractable inherited diseases. Nearly 300 gene therapies are under development, aiming to treat more than 100 diseases, according to a recent report from a drug-industry trade group.

Brammer Bio was formed in 2016 through the merger of Brammer Biopharmaceuticals and Florida Biologix, which was started a decade earlier as part of the University of Florida. The company makes so-called viral vectors. In gene therapy, a normal gene is delivered via what scientists call a vector, typically a virus genetically altered to contain human DNA.

Learn more about Thermo Fisher to acquire Brammer Bio in $1.7 billion gene-therapy deal.